SG Americas Securities
CRSP icon

SG Americas Securities’s CRISPR Therapeutics CRSP Stock Holding History

SG Americas Securities’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-200,000
Closed -$1.88M – 3447
2021
Q3 		$1.88M Buy
+200,000
New +$25.1M 0.01% 1325

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
GP
GSK plc London $602M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

SG Americas Securities's CRSP Position: Q2 2026 in Review

SG Americas Securities increased its CRISPR Therapeutics (CRSP) stake by 654% in Q2 2026, buying an estimated $1.29M and bringing the position to 28,185 shares worth $1.54M. The position accounts for ﹤0.01% of the portfolio, ranked #1635.

SG Americas Securities first reported a position in CRSP in Q3 2019 and has held it in 27 quarters since. The position peaked at $9.83M in Q2 2021. 524 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

  • SG Americas Securities held 28,185 shares of CRISPR Therapeutics worth $1.54M as of Q2 2026.
  • SG Americas Securities bought 24,448 CRISPR Therapeutics shares in Q2 2026, an estimated $1.29M.
  • CRISPR Therapeutics made up ﹤0.01% of SG Americas Securities's portfolio in Q2 2026, its #1635 holding.
  • SG Americas Securities first reported a position in CRISPR Therapeutics in Q3 2019 and has held it in 27 quarters since.
  • SG Americas Securities's CRISPR Therapeutics position peaked at $9.83M in Q2 2021.
  • 524 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on SG Americas Securities's 13F filing for Q2 2026, filed 7 Aug 2026.